List view / Grid view
The US FDA has approved Afinitor® tablets...
20 July 2012 | By Novartis
The US FDA has approved Afinitor® tablets...
Positive opinion for Afinitor® tablets...
22 June 2012 | By Novartis
Positive opinion for Afinitor® tablets...
Novartis will showcase the clinical progress of multiple marketed and…
31 May 2012 | By Novartis
Novartis will showcase the clinical progress of multiple marketed and pipeline compounds...
Results of the largest Phase III study...
7 May 2012 | By Novartis
Results of the largest Phase III study...
The FDA has approved Afinitor® tablets...
26 April 2012 | By Novartis
The FDA has approved Afinitor® tablets...
Novartis announced that the European Commission has approved Signifor®...
25 April 2012 | By Novartis
Novartis announced that the European Commission has approved Signifor®...
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU…
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...
A study found that the investigational drug Signifor®, normalized cortisol…
7 March 2012 | By Novartis
A study found that the investigational drug Signifor®, normalized cortisol levels...
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly…
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
The European Commission has approved an update to the Glivec®…
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
The US Food and Drug Administration has approved an update…
1 February 2012 | By Novartis
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...
If approved, Signifor would be the first approved medication targeting…
20 January 2012 | By Novartis
If approved, Signifor would be the first approved medication targeting Cushing's disease...
Update of the Glivec® (imatinib)* label...
20 January 2012 | By Novartis
Update of the Glivec® (imatinib)* label...
Results from two pivotal Phase III trials...
13 December 2011 | By Novartis
Results from two pivotal Phase III trials...
Phase III clinical trial data presented...
12 December 2011 | By Novartis
Phase III clinical trial data presented...
